Table 1. The association between Pfizer-23andMe–derived polygenic profiles scores for chronic pain and chronic pain in GS:SFHS and UK Biobank.

Polygenic score	Chronic Pain Grade in Generation Scotland	Chronic Pain Grade in UK Biobank
Chronic Pain score pT = 0.01	β = 3.44 x 10−2 (95%CI 2.64 x 10−3 to 7.06 x 10−2), p = 4.20 x 10−2	β = 3.47 x 10−2 (95%CI 2.47 x 10−2 to 4.46 x 10−2), p ≤ 3 x 10−4
Chronic Pain score pT = 0.05	β = 4.51 x 10−2 (95%CI 1.49 x 10−2 to 8.32 x 10−2, p = 4.3 x 10−3	β = 4.65 x 10−2 (95%CI 3.63 x 10−2 to 5.62 x 10−2), p ≤ 3 x 10−4
Chronic Pain score pT = 0.1	β = 6.18 x 10−2 (95%CI 2.84 x 10−2 to 9.35 x 10−2), p = 4.3 x 10−4	β = 4.74 x 10−2 (95%CI 3.80 x 10−2 to 5.75 x 10−2), p ≤ 3 x 10−4
Chronic Pain score pT = 0.5	β = 4.96 x 10−2 (95%CI 2.11 x 10−2 to 8.76 x 10−2), p = 4.3 x 10−4	β = 5.68 x 10−2 (95%CI 4.70 x 10−2 to 6.65 x 10−2), p ≤ 3 x 10−4

pT represents the p-value threshold (in the independent discovery GWAS sample) used to calculate the polygenic risk score. β represents standardised regression coefficient between the four polygenic risk scores and the two chronic pain phenotypes. All analyses were conducted in MCMCglmm. The 95% CI represents the 95% credible interval.